ACELRX PHARMACEUTICALS INC (ACRX)
US00444T2096 - Common Stock
ACELRX PHARMACEUTICALS INC
NASDAQ:ACRX (1/9/2024, 7:00:00 PM)
After market: 0.8719 +0.01 (+1.38%)0.86
+0.06 (+7.5%)
Company Profile
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Company Info
ACELRX PHARMACEUTICALS INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA 94063
P: 16502163500
CEO: Vincent J. Angotti
Employees: 19
Website: https://www.acelrx.com
ACRX News
4 months ago - Seeking AlphaAcelRx announces rebranding with name change to Talphera (NASDAQ:ACRX)AcelRx Pharmaceuticals announces rebranding and name change to Talphera; stock to commence trading as TLPH on Nasdaq starting January 10, 2024.
4 months ago - Talphera, Inc.AcelRx Announces Rebranding With Name Change to Talphera, Inc./PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
4 months ago - Seeking AlphaAcelRx Pharmaceuticals says CEO Angotti buys 10K shares in co (NASDAQ:ACRX)AcelRx Pharmaceuticals CEO purchases 10K shares, increasing total holdings to 101.8K. Recent insider trading activity shows 7 buys and 0 sales.
4 months ago - AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...
4 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
5 months ago - Seeking AlphaAcelRx Pharmaceuticals files for $150M mixed shelf (NASDAQ:ACRX)AcelRx Pharmaceuticals (NASDAQ:ACRX) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M.This prospectus is not an offer to...
ACRX Twits
Here you can normally see the latest stock twits on ACRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
